Background: Recent evidence supports that most non-lacunar cryptogenic strokes are embolic. Accordingly, these strokes have been designated as embolic strokes of undetermined source (ESUS).
Introduction
Cryptogenic strokes are strokes of otherwise undetermined cause and comprise about 25% all ischemic strokes. 1, 2 There is evidence that most non-lacunar cryptogenic strokes are embolic based on an ''open artery'' supplying the area of brain infarction. 3 It has long been recognized that identification of the source of the embolus is often not possible, even at autopsy. 4, 5 Advances in diagnostic techniques have identified a substantial number of potential sources of embolism in patients with non-lacunar cryptogenic stroke. 1 Multiple potential embolic sources (e.g., a patent foramen ovale, left atrial stasis, and aortic arch atherosclerosis) are often present in an individual patient, and identifying the culprit lesion cannot be done with certainty. This uncertainty has forestalled the development of randomized trials, and there has been little progress in secondary prevention of cryptogenic stroke in recent decades.
Embolic strokes of undetermined source (ESUS) have in common thromboembolic mechanisms that may be more responsive to anticoagulants than antiplatelet therapy for secondary stroke prevention. 1 This is the basis for two large international randomized trials now ongoing that are comparing new selective oral anticoagulants with aspirin. 6, 7 Relatively little is known about the frequency or clinical features of ESUS patients. 8 We undertook a global survey to determine the fraction of patients with acute ischemic stroke who meet criteria for ESUS and to characterize features of ESUS patients in different countries and across global regions.
Methods
Consecutive patients with recent ischemic stroke were sought at 20 stroke research centers in 20 different countries, targeting review of 100 patients with acute ischemic stroke at each site or until 25 patients meeting ESUS criteria were identified. Investigators were selected based on participation on the Cryptogenic Stroke/ESUS International Working Group 1 and on regional distribution in countries involved in the NAVIGATE ESUS international randomized trial (see Appendix 1 for full listing of investigators). 6 Sites were instructed to retrospectively identify consecutive inpatients evaluated for recent stroke in 2013-2014 either from hospital discharge diagnosis codes or from databases associated with acute stroke units. Criteria for ESUS were those previously published ( Table 1 ). 1 A nine-page case report form was completed for each ESUS patient by a physician provided with specific instructions and definitions. The study was compliant with local institutional research board regulations; informed consent was not required at any site for this anonymized data collection based on medical record review.
Data were analyzed according to five global regions: Europe, North America, Latin America, East Asia, and Pacific. Data from one site (Budapest, Hungary) were not included in the analyses because cardiac rhythm monitoring required for diagnosis of ESUS was not routinely carried-out (i.e., no patients met criteria for ESUS). Minor-risk cardioembolic sources were those previously described. 1 Case report forms were entered into a central database via on-line data entry or via an automated fax-based data entry system. Missing data were queried, and final data were exported to STATA 13.0 for statistical analysis. Descriptive analyses regarding the frequency of key features were done using t-test and chi-square; and limited multivariate models were done to identify independent associations.
Results

Frequency of ESUS by country and global region
Of 2144 patients with recent ischemic stroke collected from 19 stroke research centers in 19 countries, 351 (16%, 95%CI 15% to 18%) met ESUS criteria, ranging widely from 1% in Amsterdam to 36% in Paris ( Table 2 ). Of note, echocardiography (required for diagnosis) was not routinely carried out in ischemic stroke patients in Amsterdam (done in 26% of ischemic stroke patients): Excluding this site, the frequency of ESUS was 17%. Excluding 308 (14%) patients with incomplete evaluation required for ESUS diagnosis, ( Figure 1 ) the frequency of ESUS was 19%.
Among patients meeting criteria for ESUS, 40% underwent only 24-h Holter monitoring, 33% had only >24 h of inpatient cardiac telemetry, 19% had both 24-h Holter monitoring and inpatient cardiac telemetry, and 8% had either >24 h of Holter monitoring or non-telemetry extended (>24 h) of cardiac rhythm monitoring.
Comparison of the frequency of ESUS according to global region was limited by small numbers of strokes and centers, but it was relatively uniform: 16% in all regions except East Asia (21%) ( Table 3 ).
Reasons that ischemic stroke patients did not meet ESUS criteria
The most frequent reason that patients with ischemic stroke did not meet criteria for ESUS was identification of atrial fibrillation (n ¼ 590, 28% of all ischemic strokes). Additional reasons were visualized lacunar (small subcortical) infarcts (n ¼ 339, 16%), ipsilateral cervical carotid stenosis 50% (n ¼ 293, 14%), and absence of required visualization of index stroke on neuroimaging (n ¼ 115, 5%) ( Figure 1 ). In the remaining patients (n ¼ 308, 14%), insufficient evaluation was completed to assess the criteria required for ESUS diagnosis. For those with insufficient diagnostic testing to meet ESUS criteria, the mean age was 66 years and 30-day mortality was 7%.
Age and sex distribution of ESUS patients
The mean ages of ESUS patients varied across sites: Beijing had the youngest mean age (48 years) and Brussels the oldest (74 years). Overall, the age of the (20) Galway, Ireland 140 71 10 (7) Rome, Italy 91 67 19 (21) Tokyo, Japan 75 68 18 (24) Mexico City, Mexico 225 56 21 (9) Amsterdam, Netherlands 99 68 1 (1) Manila, Philippines 175 62 23 (13) Coimbra, Portugal 123 74 23 (19) Moscow, Russia 106 66 24 (23) Seoul, Korea 124 69 26 (21) Glasgow, United Kingdom 73 67 5 (7) Philadelphia, United States 120 67 18 (15) Total 2144 67 351 (16) ESUS: embolic stroke of undetermined source. See Table 1 for criteria. 
Other clinical features of ESUS patients
Among the 351 ESUS patients, hypertension, diabetes, and coronary artery disease were present in 64%, 25%, and 10%, respectively; 31% were taking antiplatelet therapy at stroke onset ( Table 4 ); 17% of the ESUS patients had a history of stroke or TIA prior to the index stroke. Median (IQR) NIHSS score near hospital admission was 4 (interquartile range 2-8); 16% received intravenous tissue plasminogen activator at the time of the index stroke. Magnetic resonance imagings were done in 77%, with an old ischemic stroke (i.e., prior to index stroke) present on magnetic resonance imaging in 40%. Transesophageal echocardiography (TEE) was undertaken in 35% of ESUS patients, with complex aortic arch plaque reported in 6% of those undergoing TEE ( Table 4 ). The 30-day mortality rate was 2% in ESUS patients compared with 10% in stroke patients with identified atrial fibrillation, and 5% in non-ESUS, non-atrial fibrillation patients. Contraindications to anticoagulant therapy were identified in 9%. At hospital discharge, 90% of ESUS patients received antiplatelet therapy, 7% anticoagulant therapy, and 3% no antithrombotic therapy ( Table 4 ).
Frequency of minor-risk potential embolic sources in ESUS patients
Of ESUS patients with anterior circulation stroke, 79% had non-stenotic cervical carotid artery plaques with a mean diameter stenosis of 17%. Among those who underwent transthoracic (precordial) echocardiography, mitral annular calcification or myxomatous changes, aortic valve stenosis or calcification, and hypokinetic/akinetic left ventricle were detected in 5%, 7%, and 4%, respectively. Of the ESUS patients who underwent transesophageal echocardiography, aortic arch atherosclerotic plaques were present in 29% and patent foremen ovale in 25%. Seventy-four per cent of ESUS patients had at least one minor-risk potential embolic source identified and 24% had two or more ( Table 5 ).
Discussion
This global survey found that ESUS patients comprise about one in six ischemic strokes at large international stroke centers (and likely higher at centers that routinely undertake the complete evaluation required to meet ESUS criteria). ESUS patients on average had relatively minor strokes with a low 30-day mortality rate (3%), and their mean age (62 years) was similar to, but significantly lower than, that of non-ESUS stroke patients without atrial fibrillation (64 years). The frequency and clinical features of ESUS patients were generally similar across global regions. Most (74%) ESUS patients had at least one minor-risk embolic source identified that could have been the cause of stroke, and nearly a quarter (24%) had two or more potential embolic sources identified. Interestingly, the prevalence of patient foramen ovale among ESUS patients undergoing transesophageal echocardiography (25%) was not increased over that expected in the general population. Excluding patients who did not undergo the complete diagnostic investigation required for ESUS diagnosis (n ¼ 308, most often lack of intracranial arterial imaging), the frequency of ESUS was 19%. Considering an estimated 25% frequency of cryptogenic ischemic strokes based on the recent literature, 1 this frequency of ESUS supports the notion that most (but not all) non-lacunar cryptogenic ischemic strokes are likely due to embolism.
The mild severity of stroke in ESUS patients is consistent with smaller emboli originating from cardiac valves and arterial sources, in contrast to larger emboli that typically originate in the cardiac chambers (e.g., left atrial thrombi in patients with atrial fibrillation). 9 Our observations regarding stroke severity are consistent with those regarding ESUS patients from the Athens Stroke Registry. 8 The substantially younger age and milder strokes of ESUS patients compared with patients with atrial fibrillation-associated stroke support different embolic origins (i.e., that undiagnosed paroxysmal atrial fibrillation is unlikely to underlie most ESUS). Alternatively, younger stroke patient may more often undergo the complete diagnostic evaluation required to meet ESUS criteria. Similarly, ischemic stroke patients with more severe strokes and/or early in-hospital mortality may not have undergone all of the required diagnostic testing. International Journal of Stroke, 11(5) International Journal of Stroke, 11 (5) Of interest, atrial fibrillation was identified in 28% of consecutive ischemic stroke patients, a higher fraction compared with hospitalized stroke patients in past decades (typically between 15% and 20%) probably due to both increasing vigilance and prevalence. Recent studies suggest that prolonged (>1 month) cardiac rhythm monitoring identifies additional patients with cryptogenic stroke who have episodes of paroxysmal atrial fibrillation, 10, 11 often very brief and of uncertain etiologic relevance. 12 Small subcortical ''lacunar'' infarcts were visualized in 16% of ischemic stroke patients and excluded the diagnosis of ESUS; unidentified lacunar infarcts were likely over-represented among the additional 5% of patients with non-visualization of strokes on neuroimaging (Figure 1 ).
Limitations of this study include participation by a limited number of selected, high-volume stroke centers. A single site in each country may not accurately reflect the spectrum of stroke. However, the study sites represented many global regions allowing characterization of ESUS patients around the world. To ensure data quality in this retrospective study, standardized data collection forms were used along with specific definitions.
Antiplatelet therapy was used for secondary stroke prevention in 90% of ESUS patients, in-line with recent guideline recommendations. [13] [14] [15] Although emboli vary in composition, almost all include, in whole or in part, thrombus, and it has been proposed that anticoagulants could offer more protection against recurrent stroke for ESUS patients than antiplatelet agents. 1 Contraindications to anticoagulation were identified in a relatively few (about 10%) ESUS patients. Currently, two large international randomized trials are underway comparing an oral factor Xa inhibitor and direct thrombin inhibitor, respectively, with aspirin for secondary prevention of stroke in ESUS patients, 6,7 as well as another phase II randomized trial. 16 In summary, this study provides a benchmark for the global frequency and clinical features of patients with ESUS. This contemporary cross-sectional sample shows generally consistent clinical features of the ESUS patients across global regions. ESUS patients comprise an important subset of ischemic stroke patients around the world: 16% fulfilled all diagnostic criteria for ESUS with additional ESUS patients likely among the 14% with incomplete diagnostic investigation. The unresolved issue of anticoagulant vs. antiplatelet prophylaxis for optimal secondary prevention in ESUS is thus relevant to large numbers of stroke patients.
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